ArticleDiabetes technology & therapeutics2026
Real-World Clinical Impact of Using Personal Glucose Targets in a Hybrid Closed-Loop System Differs According to Age.
Article in Diabetes technology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of hybrid closed-loop systems in children aged < 7 years with type 1 diabetes: a systematic review and meta-analysis of randomized controlled trials.Pediatric diabetes · 2026Pooled it
- Rethinking control-IQ+ technology: Simple strategies for easy optimization.Diabetes, obesity & metabolism · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCamAPS FX is a customizable hybrid closed-loop app with a default target glucose of 105 mg/dL. The personal glucose target is user-adjustable in 1 mg/dL increments between 80 and 198 mg/dL in 30-min segments over 24 h. We assessed the impact of different personal glucose targets on glycemic control during real-world use of CamAPS FX in different age-groups.
methodsWe retrospectively analyzed data from real-world CamAPS FX users from 11 countries across all age-groups (1 to 90 years), who used the system between December 1, 2022 and November 30, 2023, and had a minimum of 8 weeks of closed-loop use. Every sensor glucose reading was matched to the user-specified glucose target.
resultsIn total, 8604 users (mean age 32 ± 19 years, median days of data 89 [IQR 59, 119]) were included. Personal glucose targets were most frequently used by very young children (>50%), followed by school-aged children (>40%). All other age-groups used the default target 65%-68% of the time. Overall, personal glucose targets >120 mg/dL were associated with time in target range <70%. Time <70 mg/dL remained <4% across targets, apart from at the lowest (80-89 mg/dL). Older adults achieved time in range ≥70% across all targets. Very young children and young adults were only able to achieve time in range >70% with targets set below the default, which was associated with time <70 mg/dL of >4% in very young children.
conclusionsPersonal glucose targets are frequently used, with clinical impact differing depending on user-age. Adjusting glucose targets may help to achieve recommended glycemic targets and individual glycemic goals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.